Stock Overview

BridgeBio Pharma Inc (BBIO)

NASDAQ · Healthcare · Biotechnology

BridgeBio Pharma Inc is a Healthcare company with a market capitalization of $15.87B.

Market Cap
$15.87B
Price/Sales
27.4
Price/Book
118.6
EV/EBITDA
-9.0
Beta
0.98
EPS (TTM)
$-3.74
Profit Margin
-102.7%
ROE
-1790.0%
Short % of Float
16.7%
Days to Cover
5.4
52W High
$90.17
52W Low
$47.29

5-Year Price History

Latest Annual Financials · FY ending December 31, 2025

Revenue
$502.08M
Gross Profit
$473.81M
Operating Income
-$569.09M
Net Income
-$729.31M
Free Cash Flow
-$447.01M
Total Debt
$1.87B
Cash & Equivalents
$570.12M
Shareholder Equity
-$2.08B

Recent Quarterly Earnings (EPS)

QuarterReportedActual EPSEstimateSurprise
Q2 2026August 4, 2026$-0.78$-0.64-21.9%
Q1 2026May 7, 2026$-0.84$-0.62-35.5%
Q4 2025February 24, 2026$-0.94$-0.72-31.1%
Q3 2025October 29, 2025$-0.72$-0.78+7.7%
Q2 2025August 5, 2025$-0.95$-0.60-58.3%
Q1 2025April 29, 2025$-0.99$-0.89-11.1%

Short Interest

FINRA-reported short interest for semi-monthly settlement dates, published about nine business days after each settlement. Share counts are adjusted to the current split basis.

SettlementShares Short% of Shares OutDays to CoverChange
July 15, 202625,750,64913.22%5.4+6.8%
June 30, 202624,102,93812.37%4.5-5.2%
June 15, 202625,415,15013.05%8.6+4.2%
May 29, 202624,391,35912.52%9.6+0.9%
May 15, 202624,163,03712.40%8.7+0.6%
April 30, 202624,026,98212.18%7.6+6.0%
April 15, 202622,676,85611.50%13.7-3.0%
March 31, 202623,366,75211.85%14.7-0.6%

Other Biotechnology Stocks

Frequently Asked Questions

What is BridgeBio Pharma Inc's market cap?

As of August 13, 2026, BridgeBio Pharma Inc (BBIO) has a market capitalization of $15.87B.

Does BridgeBio Pharma Inc pay a dividend?

BridgeBio Pharma Inc does not currently pay a dividend.

What sector is BBIO in?

BridgeBio Pharma Inc is in the Healthcare sector, specifically the Biotechnology industry.

What is BridgeBio Pharma Inc's short interest?

As of the July 15, 2026 FINRA settlement, 25,750,649 BBIO shares were sold short, or 13.22% of shares outstanding. Days to cover: 5.4. FINRA publishes short interest twice a month, about nine business days after each settlement date.

What was BridgeBio Pharma Inc's revenue?

In its latest reported fiscal year (ending December 31, 2025), BridgeBio Pharma Inc reported revenue of $502.08M and net income of -$729.31M.

Ask your own questions about BBIO

Try mrmarket.ai free

Data as of August 13, 2026. Figures are sourced from company filings and market data and may be delayed or revised. For informational purposes only — not investment advice.